T
homas Sydenham, an English physician, is credited with the first description of acute rheumatic fever in 1685. 1 In the >300 years that have followed, notable landmarks include description of valve thickening at autopsy by Matthew Baillie in 1797, invention of the stethoscope and diagnosis of mitral valve murmurs by Rene Laennec in 1818, identification of streptococcus as a cause of pharyngitis by Theodore Billroth in 1874, recognition of the Aschoff nodule as pathognomonic of rheumatic carditis by Ludwig Aschoff in 1883, and formulation of a set of clinical criteria for the diagnosis of acute rheumatic fever by T. Duckett Jones in 1944. 2 Arguably, in modern history, the unique capability of echocardiography to allow detailed insights into cardiac structure and function must rank as a milestone for cardiology in general and rheumatic heart disease (RHD) in particular. In recognition of the utility of echocardiography, in 2015, the American Heart Association included Doppler echocardiography as a major criterion in the revised Jones criteria for the diagnosis of acute rheumatic fever. 3 Prevalence of RHD is a litmus test of a society's state of health. The persistence of RHD in disparate regions of the world bears testimony to both economic deprivation in low-income economies and unequal access to health care in middle-and high-income regions. Before the advent of echocardiography, RHD prevalence was estimated by clinical examination of cohorts at high risk-usually children of school-going age. In 1996, Anabwani and Bonhoeffer 4 were the first to sound the alarm that the prevalence of RHD using echocardiographic screening was much higher than by clinical screening alone. Several studies thereafter, using conventional or portable handheld ultrasound devices and a variety of different criteria, confirmed that the prevalence of RHD detected by echocardiographic screening was up to 10-fold higher compared with conventional methods. 5 The implications of incorporating screening echocardiography for the detection of latent RHD into routine healthcare strategies are profound and need to be considered more carefully.
The benefits of the detection of latent disease are dependent on the burden of subclinical disease, ease of diagnosis, sensitivity and specificity of screening tests, consequences for the individual of undiagnosed disease, potential for latent disease to serve as a reservoir for further spread, and evidence that specific treatment of undiagnosed disease would favorably alter long-term outcomes in a cost-effective manner. For these reasons, identification and treatment of latent tuberculosis infection, for example, are increasingly seen as an important component of the overall strategy for control and elimination of the disease. As attractive as screening echocardiography for latent RHD may appear to be, widespread acceptance of this technique into routine clinical practice outside the setting of a research environment has been hampered by several issues. Among others, these include the possibility that echocardiography may be too sensitive and lack specificity, resulting in an overdiagnosis of RHD, a lack of uniform echocardiographic criteria to confirm RHD, a lack of evidence pertaining to the natural history of latent RHD, and uncertainty over whether antibiotic treatment of latent RHD would favorably impact the prognosis of these patients. 6 In a study of 4869 Ugandan school children who underwent clinical examination and portable echocardiography, Beaton et al 7 identified 130 (2.7%) with abnormal screening echocardiography. Repeat evaluation at a tertiary hospital confirmed definite, probable, or possible RHD in 72 children, giving a positive predictive value for school-based echocardiographic screening of only 56%. Of the 72 patients, 8 had definite and 17 probable RHD, both categories requiring presence of a murmur by auscultation as a diagnostic criterion. The remaining 47 patients had possible RHD defined as origin from an RHD endemic area, no cardiac murmur, and thickened valves with significant regurgitation on echocardiography. The incremental value of screening echocardiography was therefore 0.96% (47/4869) because all the other cases would have been suspected by clinical examination anyway.
Grimaldi et al 8 conducted an echocardiographic screening program, also in Uganda, in a similar population of 5-to 17-year-old schoolchildren. This study, which occurred during the same time period and used the same echocardiographic criteria but with some differences in the study protocol, found a 10-fold higher prevalence of definite RHD compared with the Beaton study (16.5/1000 versus 1.6/1000). The diagnostic accuracy of screening echocardiography is variable and prone to many influences, including diagnostic criteria, type of screening equipment, operator experience, and prevalence of RHD in the study population. Adoption of a uniform set of diagnostic echocardiographic criteria such as those proposed by the World Heart Foundation 9 may in part alleviate some of the shortcomings of screening echocardiography for RHD, but even these criteria have been judged by some as being too complex, 10 too rigid, and lacking sensitivity.
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In this issue of Circulation, Beaton and colleagues 12 use echocardiography to offer further insights into an immensely important but hitherto largely unexplored aspect of RHD-the manner and determinants of progression of latent RHD. The current study comprised 227 school children identified with latent RHD from a prospective Ugandan RHD registry. Using the World Heart Foundation criteria for echocardiographic diagnosis of RHD combined with the American Society of Echocardiography and American Heart Association guidelines for assessment of severity of valve dysfunction, 164 patients were classified as borderline, 42 as mild-definite RHD, and 21 as moderate/severe-definite RHD. Echocardiographic progression of disease after a mean follow-up of 2.3 years was seen in 9.8%, 26%, and 52%, and regression in 46%, 45.2%, and 9.5% of patients, respectively. Risk factors for progression included more advanced disease category, younger age, and abnormality of valve morphology. Penicillin prophylaxis was administered by physician preference in a nonrandomized fashion to 47.6%, with 84.7% compliance making it difficult to evaluate the efficacy of this therapy. Based on their findings, the authors conclude that latent RHD may have a variable trajectory; those with borderline and mild-definite disease have a significant risk of progression; patients with moderate/severe-definite disease have a poor outcome and should be treated as clinically evident cases; progression may be predicted by a young age, advanced disease, and morphological valve abnormality; and finally, the pattern of evolution of latent RHD may already become apparent within the first 1 to 2 years of establishing the diagnosis. The study by Beaton et al 12 is not a randomized trial, nor is it a particularly large study, but it provides preliminary insights into the nascent stages of RHD before the occurrence of clinically advanced and largely irreversible disease. As with any novel line of investigation, the current study raises as many questions as it answers. For starters, it would have been useful to know the size of the denominator from which the cohort of latent RHD was derived, allowing one to estimate the magnitude of the problem. Furthermore, it is not patently clear whether a diagnosis of latent RHD was assigned if echocardiographic screening was positive in a patient with no history of clinical RHD or only if a careful clinical examination yielded no evidence of valvular disease. Although this distinction may appear subtle, it could sway the decision between advocating clinical examination and screening echocardiography.
Progression of RHD is known to occur as a result of both ongoing inflammation and fibrosis and recurrent bouts of acute rheumatic fever. It is for the latter reason, in fact, that long-term antibiotic prophylaxis is recommended for patients with RHD. The Beaton study 12 is well poised to assess the contribution of recurrent rheumatic fever to RHD progression and, even more intriguing, has the potential to identify serological markers of inflammation, heightened immunologic activity, and heart failure for predicting a more aggressive disease course. In the current study, Beaton et al 12 observed regression of disease in almost half of the total group but mainly in those with borderline and milddefinite disease. A study by Zühlke et al 13 of latent RHD followed for a longer period of 60 months showed regression in 52.3%, no change in 31.8%, and progression in only 15.9%. The management of such patients who regress their echocardiographic abnormalities to normal is uncertain, and indeed it is unclear whether they even should still be labeled as having RHD. The study by Beaton et al 12 makes an invaluable contribution to the overall body of data on latent RHD, but it still leaves a lingering doubt whether mass screening echocardiography should be incorporated routinely into healthcare programs in developing countries. The current study sets the stage for a randomized study evaluating the benefit of intervention with antibiotic prophylaxis in patients with latent RHD. Until such a time, governments and healthcare authorities in developing countries should be urged to establish national programs based on the ASAP (application of primary and secondary prevention strategies) approach.
14 When Pandora opened the lid of the box, she let out all evil and uncertainty, but she left behind hope and expectation, both in abundant need if we desire to eliminate the scourge of RHD.
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